BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Core Insights - BriaCell Therapeutics Corp. will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025, showcasing updated key biomarker data and survival data from its studies [1][2] Group 1: Poster Presentations - The presentations include two late-breaking clinical posters that are expected to have a significant impact on the field of breast cancer treatment [2] - The details of the poster presentations are as follows: - Late-Breaking Abstract Number: 3688, titled "Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial," scheduled for December 10, 2025, from 12:30 PM to 2:00 PM [3] - Late-Breaking Abstract Number: 3713, titled "Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine," also scheduled for December 10, 2025, from 12:30 PM to 2:00 PM [3] - Abstract Number: 1614, titled "Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer," scheduled for December 10, 2025, from 5:00 PM to 6:30 PM [3] Group 2: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4]